

For Immediate Release

30th October, 2009

SPECIAL PRODUCTS LIMITED

Special Products licenses epilepsy treatment to Phebra in Australia and New Zealand

Weybridge, Surrey, UK - **Special Products Limited**, the specialty pharma company focused on niche therapeutic areas, announced today that it has entered into an exclusive licence and distribution agreement with Phebra Pty Ltd. Under this agreement Phebra will distribute one of SPL's products for patients with status epilepticus, in Australia and New Zealand.

Status epilepticus is a medical emergency. It is defined as a condition in which there is more than 30 minutes of continuous seizure activity, or two or more seizures lasting more than 30 minutes in which the patient does not regain full consciousness between each seizure. Status epilepticus has been estimated to affect 20 per 100,000 people worldwide, which is equivalent to more than 4,000 people in Australia. According to the Australian Institute of Health and Welfare, there are more than 1,300 hospitalisations for status epilepticus every year in Australia.

"We are very pleased to have entered into this collaboration with Phebra," said **Robert Jackson, CEO of Special Products**. "This exclusive deal provides a new opportunity for Special Products and gives us an ability to reach the Australian and New Zealand markets, thus ensuring that patients in these markets, who are unable to benefit from licensed treatment, have the opportunity to access alternative treatment under the responsibility of their prescribing physician."

Commenting on the transaction, Dr Mal Eutick, CEO of Phebra, stated: "We are delighted to have obtained exclusive rights to the SPL product. The product will provide an important addition to our range of critical medicines, which we provide to the Australian and New Zealand market."

For further information:

Special Products Limited
Robert Jackson, CEO
Anthony Clayden, CFO

Tel: +44 (0) 1932 690325

For media enquiries please contact:

Buchanan Communications
Mark Court / Rebecca Skye Dietrich / Katharine Sutton

Tel: +44 (0) 20 7466 5000

Special Products Limited

Special Products Limited is a UK speciality pharmaceutical company focused on the development and distribution of medicines for patients with rare disorders and unmet medical needs. Our core skill is in the development of long shelf-life special products, which we distribute from our headquarters in Weybridge, Surrey, throughout the UK and into export markets. For further information, please visit: www.specialproducts.biz

Phebra Pty Ltd

Phebra Pty Ltd is an Australian based speciality pharmaceutical company that develops and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe. For more information about Phebra please refer to the company website at www.phebra.com